


**Product Name** : GSK778  
**Cat. No.** : PC-38071  
**CAS No.** : 2451862-42-1  
**Molecular Formula** : C<sub>30</sub>H<sub>33</sub>N<sub>5</sub>O<sub>3</sub>  
**Molecular Weight** : 511.63  
**Target** : Bromodomain  
**Solubility** : 10 mM in DMSO



## Biological Activity

GSK778 is a potent and selective inhibitor of **bromodomain (BRD) BD1** with IC<sub>50</sub> of 75 nM (BRD2-BD1), 41 nM (BRD3-BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively.

GSK778 inhibits BRD BD2 with the IC<sub>50</sub>s of 3950 nM (BRD2 BD2), 1210 nM (BRD3 BD2), 5843 nM (BRD4 BD2), and 17451 nM (BRDT BD2), respectively.

GSK778 inhibits the proliferative activity of human primary CD4<sup>+</sup> T cells and the production of effector cytokines including IFN $\gamma$ , IL-17A and IL-2.

GSK778 has a more pronounced effect on the growth and viability of MDA-453, MOLM-13, K562, MV4-11, THP-1, and MDA-MB-231 cells, GSK778 reduces the clonogenic capacity of primary human AML cells.

GSK778 offers a superior survival advantage to iBET-BD2 in the aggressive MLL-AF9 AML model. GSK778 reduces the production of anti-keyhole limpet hemocyanin (KLH) IgM and is well tolerated.

## References

Chun-Shan Liu, et al. *Int J Cancer*. 2022 Mar 3. doi: 10.1002/ijc.33989.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com